[HTML][HTML] Human leukocyte immunoglobulin-like receptors in health and disease
S Redondo-García, C Barritt, C Papagregoriou… - Frontiers in …, 2023 - frontiersin.org
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate
immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are …
immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are …
CAR T cell Toxicities: Bedside to Bench-How Novel Toxicities Inform Laboratory Investigations
Multiple chimeric antigen receptor (CAR) T cell therapies are FDA approved, and several
are under development. While effective for some cancers, toxicities remain a limitation. The …
are under development. While effective for some cancers, toxicities remain a limitation. The …
[HTML][HTML] LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway
H Wang, L Wang, H Luan, J Xiao, Z Zhao, P Yu… - Journal of Experimental …, 2024 - Springer
Abstract Background Leukocyte Ig-like receptor B family 4 (LILRB4) as an immune
checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone …
checkpoint on myeloid cells is a potential target for tumor therapy. Extensive osteolytic bone …
Beyond BCMA: newer immune targets in myeloma
M Tan, Y Chen, EL Smith - Blood Advances, 2024 - Elsevier
The identification and targeting of B cell maturation antigen (BCMA) through
immunotherapeutic strategies such as antibody-drug conjugates (ADC), chimeric antigen …
immunotherapeutic strategies such as antibody-drug conjugates (ADC), chimeric antigen …
Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches
C Jiménez, A Garrote-de-Barros… - International Journal of …, 2024 - mdpi.com
The maturation of B cells is a complex, multi-step process. During B cell differentiation,
errors can occur, leading to the emergence of aberrant versions of B cells that, finally …
errors can occur, leading to the emergence of aberrant versions of B cells that, finally …
[HTML][HTML] Gene signatures to therapeutics: Assessing the potential of ivermectin against t (4; 14) multiple myeloma
Y Song, HJ Zhang, X Song, J Geng, HY Li… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND Multiple myeloma (MM) is a terminal differentiated B-cell tumor disease
characterized by clonal proliferation of malignant plasma cells and excessive levels of …
characterized by clonal proliferation of malignant plasma cells and excessive levels of …
[HTML][HTML] Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
IG Walker, JP Roy, GSF Anderson, J Guerrero Lopez… - Leukemia, 2024 - nature.com
Despite improvements in therapy, multiple myeloma remains incurable. Chimeric antigen
receptor (CAR) T-cells have recently been demonstrated to be highly effective in the …
receptor (CAR) T-cells have recently been demonstrated to be highly effective in the …
Shifting gears with CAR T cells for autoimmune diseases
B Kale, M Khosravi-Maharlooei, F Perna - Molecular Therapy, 2024 - cell.com
Just a few weeks ago at the American Society of Hematology Annual Meeting, Mueller et al.
presented remarkable data from their ongoing study testing CD19-directed chimeric antigen …
presented remarkable data from their ongoing study testing CD19-directed chimeric antigen …